Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 2/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.31 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17719232 | 0.85 | TMPRSS2 (0.35) | TNK2 | |
| SCHEMBL18623842 | 0.85 | TMPRSS2 (0.35) | TNK2 | |
| SCHEMBL10120684 | 0.85 | TMPRSS2 (0.35) | TNK2 | |
| SCHEMBL17719370 | 0.85 | TMPRSS2 (0.35) | TNK2 | |
| SCHEMBL23960050 | 0.84 | PDE2A (0.34) | TNK2EGLN2 | |
| SCHEMBL17719377 | 0.77 | RIPK1 (0.31) | TNK2 | |
| SCHEMBL10120843 | 0.77 | RIPK1 (0.31) | TNK2 | |
| SCHEMBL17719234 | 0.77 | — | — | |
| SCHEMBL17719358 | 0.77 | — | — | |
| SCHEMBL23960007 | 0.75 | PDE2A (0.34) | TNK2EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338409-A1 | NUCLEOSIDE DRUGS FOR THE TREATMENT OR PREVENTION OF CORONAVIRUS INFECTION AND THEIR USES | MIRACURE BIOTECHNOLOGY LTD (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20230219993-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | VIGONVITA LIFE SCIENCES CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219993-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | PNP, TYMP, PIGS | TNK2 1979/4885PIK3CD 774/4885NTRK1 4110/4885 |
| US-20230338409-A1 | NUCLEOSIDE DRUGS FOR THE TREATMENT OR PREVENTION OF CORONAVIRUS INFECTION AND THEIR USES | PNP, MTAP, TYMP | TNK2 2454/4885PIK3CD 1909/4885NTRK1 4813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.